November 9, 2022
Eli Lilly Chairman and CEO David A. Ricks Eli Lilly expects its Alzheimer’s treatment donanemab to snag accelerated approval in the US “sometime in the coming months” and full approvals “sometime in ‘24” in major markets, including Japan, Chairman and...read more